# NCT03713593 (NCT03713593)

> Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03713593
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Hepatocellular
- Interventions: lenvatinib; pembrolizumab; saline placebo
- Enrollment: 794
- Primary outcome: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 30
- Podcasts: 16
- YouTube: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03713593

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03713593", "email": "<work email>"}; the inbox owner confirms by the emailed link.